Skip to main navigation Skip to search Skip to main content

A double-blind, placebo-controlled, randomized, 18-month Phase 2A study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in study participants with early Parkinson's disease

Project: Research

Project Details

StatusFinished
Effective start/end date05/27/22 → 05/26/26

Funding

  • UCB Biopharma SPRL: $198,002.61